Ascendis Pharma A/S
NASDAQ:ASND
Ascendis Pharma A/S
Other Items
Ascendis Pharma A/S
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Ascendis Pharma A/S
NASDAQ:ASND
|
Other Items
€14.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Genmab A/S
CSE:GMAB
|
Other Items
-kr9.4B
|
CAGR 3-Years
-65%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
-27%
|
||
Zealand Pharma A/S
CSE:ZEAL
|
Other Items
-kr7.5B
|
CAGR 3-Years
-1 958%
|
CAGR 5-Years
-71%
|
CAGR 10-Years
N/A
|
||
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Other Items
-kr864.4m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bioporto A/S
CSE:BIOPOR
|
Other Items
-kr207k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-37%
|
CAGR 10-Years
6%
|
||
Saniona AB
STO:SANION
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Ascendis Pharma A/S
Glance View
Ascendis Pharma A/S has established itself as a dynamic force within the biotechnology sphere, driven by a patented technology platform designed to address unmet medical needs. Founded in 2006 and headquartered in Denmark, the company has honed its focus on developing therapies to improve patients' lives by addressing significant health conditions, primarily in the fields of endocrinology and oncology. At the heart of its strategy is the TransCon technology, which revolves around prodrug methodologies that release active drug molecules at controlled rates, enhancing efficacy and reducing side effects. This platform allows Ascendis to develop extended-release versions of existing drugs, ensuring a more sustained therapeutic effect. Financially, Ascendis generates revenue by forging strategic partnerships and licensing agreements, enabling it to share in the commercialization success of its innovative pipeline products. By collaborating with larger pharmaceutical firms, Ascendis scales its impact, leveraging shared resources and expertise to bring its specialized treatments to market. Moreover, as its pipeline matures, it seeks to capitalize on successful clinical trials by moving products into commercial phases, which can result in additional income streams from direct product sales. The journey of Ascendis Pharma is emblematic of its commitment to innovation, sustainability, and delivering tangible healthcare advances through its robust technology-driven approach.
See Also
What is Ascendis Pharma A/S's Other Items?
Other Items
14.9m
EUR
Based on the financial report for Sep 30, 2024, Ascendis Pharma A/S's Other Items amounts to 14.9m EUR.
What is Ascendis Pharma A/S's Other Items growth rate?
Other Items CAGR 1Y
-95%
Over the last year, the Other Items growth was -95%.